[Form 4] Aptevo Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

Aptevo Therapeutics officer SoYoung Kwon received a grant of 11,500 restricted stock units (RSUs) reported with a transaction date of 08/06/2025. Each RSU converts one-for-one into common stock and the RSUs vest in full on the first anniversary of the grant, creating the potential issuance of 11,500 common shares at no cash price. The reported ownership following the transaction is direct. This disclosure reflects a routine equity-based compensation award to an officer rather than a cash transaction.

Insights

Corporate Governance Expert

TL;DR: Routine officer RSU award of 11,500 shares for retention and alignment; no immediate cash flow impact.

The Form 4 shows a direct grant of 11,500 RSUs to SVP SoYoung Kwon that convert 1:1 into common stock and vest in full after one year. From a governance perspective, time-based RSUs are a standard mechanism to align executive interests with shareholders and to promote retention. The filing does not disclose any performance conditions or accelerated vesting triggers. Materiality for investors depends on the company's total shares outstanding, which is not provided here, so the impact is likely neutral absent additional context.

Equity Compensation Specialist

TL;DR: 11,500 RSUs granted, direct beneficial ownership reported, 1:1 conversion and full vesting at one year; typical compensation award.

The derivative disclosure lists 11,500 RSUs acquired with a $0 exercise price and indicates the RSUs will convert into 11,500 shares of common stock. The full vest-on-anniversary schedule is straightforward and creates a clear one-year retention period. This is a standard, non-cash equity grant; specifics such as any forfeiture conditions or tax-withholding arrangements are not included in the filing. Without share count context, dilution impact cannot be quantified from this Form 4 alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kwon SoYoung

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC, BD & Corp Affairs

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		11,500		(2)	(2)	Common Stock	11,500	$0	11,500	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for APVO?

The reporting person is SoYoung Kwon, listed as SVP, GC, BD & Corp Affairs.

What was reported on the APVO Form 4 dated 08/06/2025?

A grant of 11,500 restricted stock units (RSUs) was reported with a transaction date of 08/06/2025.

How do the RSUs convert and when do they vest?

The RSUs convert one-for-one into common stock and vest in full on the first anniversary of the grant.

How many shares will the RSUs result in upon conversion?

The RSUs will convert into 11,500 shares of common stock at a 1:1 ratio.

Is the reported beneficial ownership direct or indirect?

The Form 4 reports the ownership form as Direct.